Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RORC | P51449 | 17/20 | 0.35 |
| ▸ | GPR6 | P46095 | 1/20 | 0.34 |
| ▸ | P2RX7 | Q99572 | 1/20 | 0.34 |
| ▸ | PDCD1 | Q15116 | 1/20 | 0.33 |
| ▸ | CD274 | Q9NZQ7 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23830374 | 0.92 | RORC (0.36) | RORCP2RX7 | |
| SCHEMBL23830394 | 0.89 | SCN9A (0.38) | RORC | |
| SCHEMBL23830277 | 0.89 | RORC (0.34) | RORCPDCD1CD274 | |
| SCHEMBL23830307 | 0.86 | PDE6D (0.36) | RORCP2RX7 | |
| SCHEMBL23830377 | 0.85 | CSF1R (0.40) | RORCP2RX7PDCD1CD274 | |
| SCHEMBL23830334 | 0.83 | PDE6D (0.38) | GPR6P2RX7PDCD1CD274 | |
| SCHEMBL23830407 | 0.83 | RORC (0.34) | RORC | |
| SCHEMBL23830393 | 0.82 | RORC (0.34) | RORCP2RX7 | |
| SCHEMBL23830404 | 0.82 | SCN9A (0.39) | RORC | |
| SCHEMBL23830398 | 0.81 | PDE6D (0.41) | RORCP2RX7PDCD1CD274 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210292333-A1 | CONDENSED AZAHETEROARYL COMPOUNDS HAVING ANTIBACTERIAL ACTIVITY AGAINST TUBERCULOSIS BACTERIA | CADILA HEALTHCARE LIMITED (IN) | 2021-09-23 | — | — | US | claimed |
| CN-112543757-A | Condensed azaheteroaryl compounds having antibacterial activity against tubercle bacillus | 卡迪拉保健有限公司 | 2021-03-23 | — | — | CN | claimed |
| US-20210292333-A1 | CONDENSED AZAHETEROARYL COMPOUNDS HAVING ANTIBACTERIAL ACTIVITY AGAINST TUBERCULOSIS BACTERIA | CADILA HEALTHCARE LIMITED (IN) | 2021-09-23 | — | — | US | disclosed |
| CN-112543757-A | Condensed azaheteroaryl compounds having antibacterial activity against tubercle bacillus | 卡迪拉保健有限公司 | 2021-03-23 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210292333-A1 | CONDENSED AZAHETEROARYL COMPOUNDS HAVING ANTIBACTERIAL ACTIVITY AGAINST TUBERCULOSIS BACTERIA | DPEP1, SAT1, PEPD | RORC 923/4885GPR6 1957/4885P2RX7 3325/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.